FTC OKs Sun's Taro Buy After Divestitures

Law360, New York (August 13, 2008, 12:00 AM EDT) -- United States antitrust regulators have challenged Sun Pharmaceutical Ltd.’s proposed acquisition of its generic drug manufacturing competitor Taro Pharmaceutical Industries Ltd., claiming the deal may result in higher prices for generic versions of the anti-convulsant drug carbamazepine in the U.S.

The U.S. Federal Trade Commission said Wednesday that it had filed a complaint in an effort to halt the acquisition, but said Sun had agreed to enter into a consent order, putting to rest the FTC’s fears of any anti-competitive effects resulting from Sun and Taro’s...
To view the full article, register now.